Presentation to the Fall CI4CC meeting in Utah. CI4CC Moonshot Blue Ribbon Panel Report. Highlights of Vice President Biden's Cancer Moonshot and the NCI Blue Ribbon Panel Recommendations.
Converged IT Summit - NCI Data SharingWarren Kibbe
Cancer Moonshot, Data Sharing, Genomic Data Commons, NCI Cloud Pilots, Cancer Research Data Ecosystem, technology advances, chemotherapy advances, MATCH, NCI Cancer Moonshot Blue Ribbon Panel Recommendations
Nci clinical genomics data sharing ncra sept 2016Warren Kibbe
Gave an update on the Cancer Research Data Ecosystem, the Genomic Data Commons, Cloud Pilots, incentives for data sharing in cancer research to the NCI Council of Research Advocates (NCRA) on Monday, September 26th, 2016
Cancer Moonshot, Data sharing and the Genomic Data CommonsWarren Kibbe
Gave the inaugural Informatics Grand Rounds at City of Hope on September 8th. NIH Commons, Genomic Data Commons, NCI Cloud Pilots, Cancer Moonshot and rationale for changing incentives around data sharing all discussed.
Converged IT Summit - NCI Data SharingWarren Kibbe
Cancer Moonshot, Data Sharing, Genomic Data Commons, NCI Cloud Pilots, Cancer Research Data Ecosystem, technology advances, chemotherapy advances, MATCH, NCI Cancer Moonshot Blue Ribbon Panel Recommendations
Nci clinical genomics data sharing ncra sept 2016Warren Kibbe
Gave an update on the Cancer Research Data Ecosystem, the Genomic Data Commons, Cloud Pilots, incentives for data sharing in cancer research to the NCI Council of Research Advocates (NCRA) on Monday, September 26th, 2016
Cancer Moonshot, Data sharing and the Genomic Data CommonsWarren Kibbe
Gave the inaugural Informatics Grand Rounds at City of Hope on September 8th. NIH Commons, Genomic Data Commons, NCI Cloud Pilots, Cancer Moonshot and rationale for changing incentives around data sharing all discussed.
NCI Cancer Genomics, Open Science and PMI: FAIR Warren Kibbe
Talk given to the NLM Fellows on July 8, 2016. Touches on Cancer Genomics, Open Science and PMI: FAIR in NCI genomics thinking and projects. Includes discussion of the Genomic Data Commons (GDC), Cancer Data Ecosystem, Data sharing, and the NCI cancer clinical trials open API.
National Cancer Data Ecosystem and Data SharingWarren Kibbe
Grand Rounds at the Siteman Cancer Center at Washington University. Highlighting the Genomic Data Commons and the National Cancer Data Ecosystem defined by the Cancer Moonshot Blue Ribbon Panel
Day 2 Big Data panel at the NIH BD2K All Hands 2016 meetingWarren Kibbe
Big data in oncology and implications for open data, open science, rapid innovation, data reuse, reproducibility and data sharing. Cancer Moonshot, Precisions Medicine Initiative (PMI), the Genomic Data Commons, NCI Cloud Pilots, NCI-DOE Pilots, and the Cancer Research Data Ecosystem.
NCI Cancer Imaging Program - Cancer Research Data EcosystemWarren Kibbe
Given to the NCI Cancer Imaging Program monthly telecon on January 9th, 2017. NCI Genomic Data Commons, Beau Biden Cancer Moonshot Blue Ribbon Panel, Cancer Research Data Ecosystem and the role of imaging in precision medicine
DOE-NCI Pilots presentation at the Frederick National Laboratory Advisory Com...Warren Kibbe
May 2016 FNLAC presentation of the DOE-NCI partnership around three pilots focused on existing projects in NCI and existing NSCI directives and activities in DOE.
2016 Data Commons and Data Science Workshop June 7th and June 8th 2016. Genomic Data Commons, FAIR, NCI and making data more findable, publicly accessible, interoperable (machine readable), reusable and support recognition and attribution
May 2016 NCI Cancer Center Directors meeting. Data Sharing and the Cancer Genomic Data Commons (GDC). Focus is on cancer genomic and clinical phenotype data.
Keynote at NVIDIA GPU Technology Conference in D.C.Jerry Lee
Presentation at NVIDIA GPU Technology Conference in D.C. on how the Cancer Moonshot Task Force under Vice President Biden is using AI to help end cancer as we know it. Dr. Lee will discuss global efforts to empower A.I. and deep learning for oncology with larger and more accessible datasets.
US Federal Cancer Moonshot- One Year LaterJerry Lee
Presentation from former Cancer Moonshot Data and Technology Track Co-chairs Jerry S.H. Lee, PhD (NCI, former OVP) and Dimitri Kusnezov, PhD (DOE) to update on efforts that will help realize the Data/Tech Track's vision of a national learning healthcare system for cancer. These include NCI/DOE pilots, DOE/VA pilot, NCI GDC, DoD/VA/NCI APOLLO, NCI/GSK ATOM, and BloodPAC.
Design Thinking: Finding Problems Worth Solving In HealthAdam Connor
Ideas for new devices and services can come from anywhere. But great ideas come from aligning solutions with real value and desirability for people. Design thinking provides a set of principles and structure that can act as scaffolding for teams to find and understand challenges and opportunities to focus on fan find solutions for.
NCI Cancer Genomics, Open Science and PMI: FAIR Warren Kibbe
Talk given to the NLM Fellows on July 8, 2016. Touches on Cancer Genomics, Open Science and PMI: FAIR in NCI genomics thinking and projects. Includes discussion of the Genomic Data Commons (GDC), Cancer Data Ecosystem, Data sharing, and the NCI cancer clinical trials open API.
National Cancer Data Ecosystem and Data SharingWarren Kibbe
Grand Rounds at the Siteman Cancer Center at Washington University. Highlighting the Genomic Data Commons and the National Cancer Data Ecosystem defined by the Cancer Moonshot Blue Ribbon Panel
Day 2 Big Data panel at the NIH BD2K All Hands 2016 meetingWarren Kibbe
Big data in oncology and implications for open data, open science, rapid innovation, data reuse, reproducibility and data sharing. Cancer Moonshot, Precisions Medicine Initiative (PMI), the Genomic Data Commons, NCI Cloud Pilots, NCI-DOE Pilots, and the Cancer Research Data Ecosystem.
NCI Cancer Imaging Program - Cancer Research Data EcosystemWarren Kibbe
Given to the NCI Cancer Imaging Program monthly telecon on January 9th, 2017. NCI Genomic Data Commons, Beau Biden Cancer Moonshot Blue Ribbon Panel, Cancer Research Data Ecosystem and the role of imaging in precision medicine
DOE-NCI Pilots presentation at the Frederick National Laboratory Advisory Com...Warren Kibbe
May 2016 FNLAC presentation of the DOE-NCI partnership around three pilots focused on existing projects in NCI and existing NSCI directives and activities in DOE.
2016 Data Commons and Data Science Workshop June 7th and June 8th 2016. Genomic Data Commons, FAIR, NCI and making data more findable, publicly accessible, interoperable (machine readable), reusable and support recognition and attribution
May 2016 NCI Cancer Center Directors meeting. Data Sharing and the Cancer Genomic Data Commons (GDC). Focus is on cancer genomic and clinical phenotype data.
Keynote at NVIDIA GPU Technology Conference in D.C.Jerry Lee
Presentation at NVIDIA GPU Technology Conference in D.C. on how the Cancer Moonshot Task Force under Vice President Biden is using AI to help end cancer as we know it. Dr. Lee will discuss global efforts to empower A.I. and deep learning for oncology with larger and more accessible datasets.
US Federal Cancer Moonshot- One Year LaterJerry Lee
Presentation from former Cancer Moonshot Data and Technology Track Co-chairs Jerry S.H. Lee, PhD (NCI, former OVP) and Dimitri Kusnezov, PhD (DOE) to update on efforts that will help realize the Data/Tech Track's vision of a national learning healthcare system for cancer. These include NCI/DOE pilots, DOE/VA pilot, NCI GDC, DoD/VA/NCI APOLLO, NCI/GSK ATOM, and BloodPAC.
Design Thinking: Finding Problems Worth Solving In HealthAdam Connor
Ideas for new devices and services can come from anywhere. But great ideas come from aligning solutions with real value and desirability for people. Design thinking provides a set of principles and structure that can act as scaffolding for teams to find and understand challenges and opportunities to focus on fan find solutions for.
In this update of his past presentations on Mobile Eating the World -- delivered most recently at The Guardian's Changing Media Summit -- a16z’s Benedict Evans takes us through how technology is universal through mobile. How mobile is not a subset of the internet anymore. And how mobile (and accompanying trends of cloud and AI) is also driving new productivity tools.
In fact, mobile -- which encompasses everything from drones to cars -- is everything.
Who I Am Makes A Difference
A teacher in New York decided to honor each of her high school seniors for the difference they made in her life. Then she presented each of them with a Blue Ribbon imprinted with gold letters which read, "Who I Am Makes A Difference.”™ Afterwards the teacher gave each of the students three more ribbons to acknowledge others to see what impact it would have in their community. They were to follow up on the results, see who honored whom and report back to the class the following week.
Failure is not an option, or, why you need to ask 'Why?" more often.Alessandro Galetto
We should answer a simple question: "Why companies are built and managed in the way we know?".
In this presentation I will give my answer from an historic, scientific and economic perspective, and, at the same, I will try to show why other models are possible.
Different organisational models are not only possible, but needed when the current models are causing so much pain in modern companies.
We need to reinvent the way company works as well as we must reinvent the definition of career in the 21st century.
We have so many tools and the higher amount of technology that we can use to shape the future of our companies. Which is the reason why we are not doing anything about it?
Even if the presentation is definitely focused on the Italian market it contains elements and ideas that have a broader ranged of applicability.
And, as always, it's not too serious.
I used this presentation for my talk at the Better Software 2013 conference in Florence.
WCRF International Continuous Update Project (CUP). Presentation given by Giota Mitrou PhD MSc, Head of Research Funding and Science Activities, World Cancer Research Fund International (WCRF International).
Participation of the population in decisions about their health and in the pr...Pydesalud
Póster presentado por Lilisbeth Perestelo en el congreso Summer Institute for Informed Patient Choice (SIIPC14) celebrado del 25 al 27 de junio de 2014 en Dartmouth, Hanover (EEUU). Web: http://siipc.org
Contacto: lperperr@gobiernodecanarias.org
Advancing Convergence and Innovation in Cancer ResearchJerry Lee
Describes NCI's Center for Strategic Scientific Initiatives activities (2005 - 2017) as well as data and technology activities of the 2016 White House Cancer Moonshot Task Force (2016 - 2017).
Kim Solez Tissue Engineering Pathology Meets Human Cell Atlas a Glimpse into ...Kim Solez ,
Dr. Kim Solez presents "Tissue Engineering Pathology Meets Aviv Regev's Human Cell Atlas: A Glimpse Into the Future of Pathology" on March 8th, 2017 at the University of Alberta in Edmonton, Alberta, Canada Copyright (c) 2017, JustMachines Inc.
Advancing Innovation and Convergence in Cancer Research: US Federal Cancer Mo...Jerry Lee
Special Seminar at the 8th Taiwan Biosignatures Workshop to share overall work of NCI's Center for Strategic Scientific Initiatives since 2003 as well as CSSI's influence on select projects initiated by the 2016 WH Cancer Moonshot Task Force that include Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) network, International Cancer Proteogenome Consortium, and the Blood Profiling Atlas in Cancer (BloodPAC) commons.
As part of the 4th Annual Early Age Onset CRC Summit theNational Colorectal Cancer Roundtable (NCCRT) Family History and Early Onset Task Group hosted a Special Symposium focused on the importance of Family Health History for colorectal cancer, including advanced adenomas, and its importance in preventing colorectal cancer. The Symposium included presentations on the current challenges and opportunities surrounding ascertainment and documentation of actionable family health history information in primary care.
Transition transplant path to tissue engineer path new banff class 2017 Kim Solez ,
Kim Solez "The transition between transplant pathology and tissue engineering pathology: Beginning a new Banff classification - 2017 Update". ATI Fellows Rounds Presentation Spept 12 2017
Similar to CI4CC Moonshot Blue Ribbon Panel Report 20161010 (20)
Overview of the NIH-funded RADx-UP - Rapid Acceleration of Diagnostics - Underserved Populations (RADx-UP) Coordination and Data Collection Center (CDCC) with a focus on the Common Data Elements used to gather data across the RADx-UP Consortium for COVID-19 testing.
RADx-UP CDCC presentation for the NIH Disaster Interest GroupWarren Kibbe
Presentation on the RADx-Underserved Populations Coordination and Data Collection Center with an emphasis on how it will help understand and reduce the disparities associated with the COVDI-19 pandemic
Data Harmonization for a Molecularly Driven Health SystemWarren Kibbe
Maximizing the value of data, computing, data science in an academic medical center, or 'towards a molecularly informed Learning Health System. Given in October at the University of Florida in Gainesville
Data Harmonization for a Molecularly Driven Health SystemWarren Kibbe
Seminar for Dr. Min Zhang's Purdue Bioinformatics Seminar Series. Touched on learning health systems, the Gen3 Data Commons, the NCI Genomic Data Commons, Data Harmonization, FAIR, and open science.
Drivers for data sharing in funding of biomedical research. Importance of data sharing on open science, innovation, reproducibility that is enabled by digital technologies and data science.
Data in precision oncology SAMSI Precision Medicine Meeting mar 2019Warren Kibbe
Talk at the March 14-15 2019 SAMSI Advances in Precision and Personalized Medicine held as part of the Program on Statistical, Mathematical, and Computational Methods for Precision Medicine (PMED) at NCSU, Raleigh, NC
The Gram stain is a fundamental technique in microbiology used to classify bacteria based on their cell wall structure. It provides a quick and simple method to distinguish between Gram-positive and Gram-negative bacteria, which have different susceptibilities to antibiotics
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
1. Blue Ribbon Panel Report 2016
CI4CC in Utah
October 10th, 2016
www.cancer.gov/brp
Warren A. Kibbe, PhD
warren.kibbe@nih.gov
@wakibbe
2. NCI and The Cancer Moonshot
Town Hall
October 5, 2016
Douglas R. Lowy
Acting Director, National Cancer Institute,
National Institutes of Health
3. 3
An Exciting Time for Cancer Research
Commitment of current
Administration
Precision Medicine Initiative
(PMI®) in oncology
Cancer Moonshot
Strong, bipartisan Congressional
support for cancer research
4. 4
Relationship Between Bypass Budget and Blue Ribbon
Panel Report
Bypass Budget addresses NCI’s
entire research portfolio
Lays out the plan for NCI’s
continued investment in cancer
research
Cancer Moonshot is a unique
opportunity to enhance cancer
research in specific areas that are
poised for acceleration
The BRP report made 10 bold,
yet feasible, recommendations
that will fast-track initiatives if
infused with Moonshot funding
7. 7
Focus on specific cancers with health
disparities
Some examples: lung cancer, colorectal
cancer, liver cancer, breast cancer, prostate
cancer, multiple myeloma
Identify the risk factors and their relative
contribution to the disparities: biologic
factors, life-style factors, health care
access/utilization
Explore efforts to mitigate the risk factors
8. ■ White
♦ Black
▲ API
* AI/AN
● Hispanic*
*Hispanic is not mutually exclusive from other groups
Incidence data from SEER 13 1992-2010, Mortality data from NCHS
8
*Hispanic is not mutually exclusive from other groups
Incidence data from SEER 13 1992–2013, Mortality data from NCHS
Colon & Rectum
0
10
20
30
40
50
60
70
80
Incidencerateper100,000
Year of diagnosis
SEER Incidence
0
10
20
30
40
50
60
70
80
Mortalityrateper100,000
Year of death
US Mortality
9. 9
“…Mutations in a set of 15…genes appear to be
strongly preferentially associated with CRCs arising in
AA versus Caucasian individuals, suggesting an
important difference in the mutational landscapes of
CRCs arising in different ethnic groups. “
Guda et al., 2015. Proc. Natl. Acad. Sci. 112:1149
10. ■ White
♦ Black
▲ API
* AI/AN
● Hispanic*
*Hispanic is not mutually exclusive from other groups
Incidence data from SEER 13 1992-2010, Mortality data from NCHS
10
*Hispanic is not mutually exclusive from other groups
Incidence data from SEER 13 1992–2013, Mortality data from NCHS
Myeloma
0
3
6
9
12
15
Incidencerateper100,000
Year of diagnosis
SEER Incidence
0
3
6
9
12
15
Mortalityrateper100,000
Year of death
US Mortality
11. 11
Some
Principles to
Follow
Develop better genomic,
biologic, environmental,
and treatment response
information about cancer
in minority populations
Minority populations
represented in clinical
trials & preclinical
cancer models
Ensure from the
beginning that
appropriate minority
representation will be
included
12. Two new NCI research initiatives
Early onset malignancy initiative: the first
minority-based cancer tissue bank; early onset
tumors; collect information on treatment,
response, and outcome
Detailed molecular characterization of fully
annotated tumors
Organized through NCORP (NCI Community
Oncology Research Program)
Develop new cancer models from tumors of
minority patients
13. 13
Goals of the Cancer Moonshot
Accelerate progress in cancer, including prevention & screening
From cutting edge basic research to wider uptake of standard of
care
Encourage greater cooperation and collaboration
Within and between academia, government, and private sector
Enhance data sharing
(Presidential Memo 2016)
14. 14
Cancer Moonshot
Federal Task Force
Vice President’s Office
“Blue Ribbon Panel”
Working Groups
National Cancer Advisory Board
NCI/NIH
Vice President’s Cancer Moonshot Workflow
15. 15
Cancer Moonshot: Why now?
The science is ready, and would benefit from
a major infusion of additional resources
Lots of opportunities for bold, but feasible,
initiatives that could have important
implications for our understanding of cancer
and for patients through improved prevention,
screening, and treatment
Immunotherapy has come of age
16. 16
Unintentional communication that cancer is
now a technological/engineering problem?
Terms such as “precision medicine”: do they
inadvertently imply understanding that is greater
than it is, and that advances in cancer no longer
depend on scientific discovery of the unknown?
Immune checkpoint inhibitors: based on
understanding immune regulation, but still much
that we don’t understand
Emphasize: progress in cancer remains heavily
dependent on developing new knowledge
17. 17
An Opportunity for Focused
Research to Accelerate Progress
Take advantage of current advances in the
understanding of cancer and recent technological
innovation
Apply the knowledge and innovation to focus on
specific projects that can have a substantial impact
on understanding and/or improvement for patients
NB: NCI will continue to support a great deal of
other meritorious research
19. cancer.gov/brp Blue Ribbon Panel Report 2016
Blue Ribbon Panel
Recommendations focus on what we believe can be accelerated now by Cancer
Moonshot funding
Recommendations are limited – they do not touch the entire spectrum of what
NCI supports!
The recommendations do not include implementation!
The BRP recommendations have identified opportunities that the community thinks
are important. NCI plans to implement them. But, the rate and extent are
dependent on the level of appropriations we receive!
In the near term, there will be a call for NCI scientific staff to get engaged to help
design programs and design implementation by participating in working groups.
20. Co-Chairs
Tyler Jacks* Elizabeth Jaffee* Dinah Singer
MIT Johns Hopkins NCI
Peter C. Adamson, M.D.*
Children's Hospital of Philadelphia
James Allison
MD Anderson
David Arons
National Brain Tumor Society
Mary Beckerle
Univ. of Utah
Mitchel Berger*
UCSF
Jeffrey Bluestone
Parker Institute
Chi Dang*
U. Penn
Mikael Dolsten
Pfizer
*NCAB/BSA member
Augusto Ochoa
Louisiana State Univ.
Jennifer Pietenpol
Vanderbilt Univ.
Angel Pizzaro
Amazon Web Services
Barbara Rimer
UNC
Charles Sawyers*
MSK
Ellen Sigal
Friends of Cancer Research
Patrick Soon-Shiong
NantWorks
Wai-Kwan Alfred Yung
MD Anderson
James Downing
St. Jude Hospital
Levi Garraway
Harvard Medical School
Gad Getz
Broad Institute
Laurie Glimcher
Weill Cornell
Lifang Hou
Northwestern
Neal Kassell
Univ. Va.
Elena Martinez*
UCSD
Deborah Mayer
UNC
Edith Mitchell
Thomas Jefferson Univ.
Blue Ribbon Panel
21. cancer.gov/brp Blue Ribbon Panel Report 2016
Charge to Blue Ribbon Panel
“The Blue Ribbon Panel … will provide expert advice on the vision, proposed
scientific goals, and implementation of the National Cancer Moonshot. ..The
panel may also recommend other cancer research activities to enhance this
effort.
“The Panel will provide an intensive examination of the opportunities and
impediments in cancer research… the Panel may call upon special
consultants, assemble ad hoc work groups … Findings and recommendations
of the Panel will be reported to the NCAB.
(Presidential Memo 2016)
22. Working Group Co-Chair NCI Staff
Cancer Immunology Liz Jaffee,
Jim Allison
Toby Hecht,
Kevin Howcroft
Precision Prevention and
Early Detection
Mary Bekerle,
Jennifer Pietenpol
Elisa Woodhouse
Tracy Lively
Tumor Evolution Chi Dang,
Levi Garraway
Joanna Watson, Suresh Mohla,
Tony Dickherber
Clinical Trials Charles Sawyers,
Mitch Berger
Jeff Hildesheim
Meg Mooney
Implementation Sciences Elena Martinez,
Augusto Ochoa
Bob Croyle, Worta McCaskill-
Stevens
Pediatric Cancer Peter Adamson
Jim Downing
Judy Mietz
Malcolm Smith
Enhanced Data Sharing Angel Pizarro
Gaddy Getz
Juli Klemm
Betsy Hsu, Jennifer Couch
BRP Working Groups
23. cancer.gov/brp Blue Ribbon Panel Report 2016
Blue Ribbon Panel Working Groups
• The seven Working Groups had 12-15 members.
• In total almost 150 individuals were engaged in the Working
Groups, including academic researchers, clinicians, industry
representatives and advocates.
• Charge was to generate 2-3 recommendations of major scientific
opportunities that are poised for acceleration.
• The Working Groups met almost weekly to discuss and formulate
their recommendations
24. cancer.gov/brp Blue Ribbon Panel Report 2016
Scientific and Community Outreach Activities
Goal:
Provide opportunities for the public and experts ways to submit ideas
Increase the public’s participation in the Cancer Moonshot
Approaches:
Online public idea repository
One-on-one public input: email
BRP Listening sessions
Professional conferences
Response:
Over 1600 ideas received from the public!
25. cancer.gov/brp Blue Ribbon Panel Report 2016
Charge to Blue Ribbon Panel
“The Blue Ribbon Panel … will provide expert advice on the vision, proposed
scientific goals, and implementation of the National Cancer Moonshot. ..The
panel may also recommend other cancer research activities to enhance this
effort.
“The Panel will provide an intensive examination of the opportunities and
impediments in cancer research… the Panel may call upon special
consultants, assemble ad hoc work groups … Findings and recommendations
of the Panel will be reported to the NCAB.
(Presidential Memo 2016)
26. cancer.gov/brp Blue Ribbon Panel Report 2016
The 7 Working Groups submitted a total of 14 recommendations
All 14 were discussed at the July 20 meeting of the Blue Ribbon Panel
Thirteen were approved as “Moonshot recommendations”
One recommendation was converted to a demonstration project
Other recommendations across working groups were combined to form the 10
final recommendations in the report
Overview of Blue Ribbon Panel Report
27. cancer.gov/brp Blue Ribbon Panel Report 2016
In the final recommendations, the following recommendations were combined:
Pediatrics Cancer and Tumor Evolution Working Groups both recommended
efforts to identify new therapeutic targets to overcome cancer resistance.
Tumor Evolution, Cancer Immunology and Precision Prevention Working
Groups proposed generation of human atlases of cancer.
Both the Precision Prevention and Implementation Science Working Groups
focused on the importance of screening.
Development of technologies cited throughout the recommendations was
combined into a single recommendation
Overview of Blue Ribbon Panel Report
28. cancer.gov/brp Blue Ribbon Panel Report 2016
The Report summarizes these recommendations of exceptional
research opportunities that could lead to powerful advances in our
understanding of cancer
Three sidebars highlight proposed demonstration projects
The online Report includes all recommendations in their entirety at
https://cancer.gov/brp
Overview of Blue Ribbon Panel Report (Cont.)
29. cancer.gov/brp Blue Ribbon Panel Report 2016
Summary of the Recommendations
A. Network for direct patient engagement:
• Enlist patients in federated network that includes patient tumor profiling data
and “pre-registers” patients for clinical trials.
B. Cancer immunotherapy translational science network.
• Organize a network to discover and evaluate novel immune-based
approaches for adult and pediatric cancers, and eventually develop vaccines.
C. Therapeutic target identification to overcome drug resistance.
• Launch interdisciplinary studies to delineate mechanisms that lead cancer
cells to become resistant to previously effective treatments.
D. Creation of a national cancer data ecosystem.
• Create an ecosystem to collect, share, and interconnect datasets.
30. cancer.gov/brp Blue Ribbon Panel Report 2016
Summary of the Recommendations
E. Fusion oncoproteins in pediatric cancer.
• Improve understanding of the abnormal fusion proteins that result from
chromosomal translocations and drive many pediatric cancers.
F. Symptom management research.
• Support research to accelerate development of guidelines for management of
patient-reported symptoms to improve quality of life and adherence to
treatment regimens.
G. Precision prevention and early detection:
• Implementation of evidence-based approaches. Conduct implementation
science research to encourage broader adoption of HPV vaccination,
colorectal cancer screening, and tobacco cessation.
31. cancer.gov/brp Blue Ribbon Panel Report 2016
Summary of the Recommendations (continued)
H. Retrospective analysis of biospecimens from patients treated with standard
of care.
• Analyze biopsies to learn which features predict outcome to better plan
treatment for future patients.
I. Creation of human tumor atlas.
• Catalog genetic lesions and cellular interactions in tumor/immune/other cells
in tumor microenvironment.
J. Development of new enabling technologies.
• Support development of technologies to accelerate testing of therapies and
tumor characterization.
32. cancer.gov/brp Blue Ribbon Panel Report 2016
Summary of the Demonstration Projects
Prevention: Lynch Syndrome Demonstration Project
• A national effort to systematically screen all CRC and endometrial cancer
patients for Lynch syndrome (LS)
• First degree relatives of patients with LS would be given the option to be
screened and provided with genetic counseling
Therapy: Pediatric Cancer Immunotherapy Network Demonstration Project
• A national pediatric immunotherapy clinical trials network to facilitate the
testing of new immunotherapy approaches in childhood cancer
• Establish a robust research pipeline to advance pediatric immunotherapy
Emergent Technologies: Tumor Pharmacotyping Demonstration Project
• Develop intra- and extra-tumoral technologies for determining the most
effective therapeutic agents for individual patients
33. cancer.gov/brp Blue Ribbon Panel Report 2016
National network of patient biological and clinical data
Prevention
Health disparities research
Biomarkers
Development of technology and preclinical models
Data sharing, analytics and predictive computational modeling
Collaboration; public-private partnerships
Cross-Cutting Themes
34. cancer.gov/brp Blue Ribbon Panel Report 2016
Cross-Cutting Themes (Cont.)
Improving the lives of patients is the major cross-cutting theme of the
recommendations
Advocates are essential partners in engaging patients to help
achieve the scientific priorities.
35. cancer.gov/brp Blue Ribbon Panel Report 2016
Policy issues identified by the BRP as barriers (e.g. coverage and reimbursement;
uniform informed consent) have been forwarded to the Task Force for consideration.
Implementation will depend on the extent to which these barriers are
addressed.
Extent and rate of implementation will depend on Congressional appropriations
Next Steps
36. Cancer data ecosystem
Well characterized
research data sets Cancer cohorts Patient data
EHR, lab data, imaging,
PROs, smart devices,
decision support
Learning from every
cancer patient
Active research
participation
Research information
donor
Clinical Research
Observational studies
Proteogenomics
Imaging data
Clinical trials
Discovery
Patient engaged
Research
Surveillance
Big Data
Implementation research
SEER
37. 37
Cancer Research Data Commons Ecosystem
Genomic
Data Commons
Data Standards
Validation and Harmonization
Imaging
Data Commons
Proteomics
Data Commons
Clinical Data
Commons
(Cohorts / Indiv.)
SEER
(Populations)
Data Contributors and Consumers
Researchers PatientsClinician
s
Institutions